Tobira Therapeutics is a privately-held biopharmaceutical company developing and commercializing innovative therapies for treatment of HIV infection. The company's lead development candidate is cenicriviroc (CVC or TBR-652), a novel, oral, once-daily, fixed-dose combinable, dual inhibitor of chemokine receptors CCR5 and CCR2. Tobira is evaluating cenicriviroc for treatment of HIV infection in treatment-naive patients.Tobira has completed a randomized, double-blinded, double-dummy and controlled Phase 2b study of CVC in treatment-naive HIV-infected individuals, and is advancing development of cenicriviroc to Phase 3 registrational studies. Tobira has financial backing from a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.